Search results for "11 Medical and Health Sciences"

showing 10 items of 67 documents

Histone post-translational modifications as potential therapeutic targets for pain management

2021

Effective pharmacological management of pain associated with tissue pathology is an unmet medical need. Transcriptional modifications in nociceptive pathways are pivotal for the development and the maintenance of pain associated with tissue damage. Accumulating evidence has shown the importance of the epigenetic control of transcription in nociceptive pathways via histone post-translational modifications (PTMs). Hence, histone PTMs could be targets for novel effective analgesics. Here, we discuss the current understanding of histone PTMs in the modulation of gene expression affecting nociception and pain phenotypes following tissue injury. We also provide a critical view of the translationa…

Farmacologiadorsal root ganglionPharmacological managementPainToxicologyBioinformaticsHistonesTissue damageHumansPain ManagementMedicinenociceptionPharmacology & PharmacyEpigeneticsspinal dorsal horn11 Medical and Health Sciencesneuropathic painPharmacologyepigeneticsbiologybusiness.industry06 Biological SciencesPain managementgene transcriptionNociceptionHistoneNeuropathic painPosttranslational modificationbiology.proteinbusinessProtein Processing Post-TranslationalGenèticaTrends in Pharmacological Sciences
researchProduct

Role of the Netrin-like Domain of Procollagen C-Proteinase Enhancer-1 in the Control of Metalloproteinase Activity

2010

The netrin-like (NTR) domain is a feature of several extracellular proteins, most notably the N-terminal domain of tissue inhibitors of metalloproteinases (TIMPs), where it functions as a strong inhibitor of matrix metalloproteinases and some other members of the metzincin superfamily. The presence of a C-terminal NTR domain in procollagen C-proteinase enhancers (PCPEs), proteins that stimulate the activity of astacin-like tolloid proteinases, raises the possibility that this might also have inhibitory activity. Here we show that both long and short forms of the PCPE-1 NTR domain, the latter beginning at the N-terminal cysteine known to be critical for TIMP activity, show no inhibition, at …

Glycobiology and Extracellular MatricesMatrix metalloproteinaseBiochemistryBONE MORPHOGENETIC PROTEIN-1AdamalysinFIBRILLAR PROCOLLAGENSTolloid ProteinaseExtracellular Matrix Proteins0303 health sciencesADAMTSFRIZZLED-RELATED PROTEINS030302 biochemistry & molecular biologyTissue Inhibitor of Metalloproteinases11 Medical And Health SciencesALPHA-CONVERTING-ENZYMEI PROCOLLAGENADAM ProteinsExtracellular MatrixPLASMINOGEN ACTIVATIONBiochemistryCollagen03 Chemical SciencesLife Sciences & BiomedicineProcollagenBiochemistry & Molecular BiologyTERMINAL DOMAINTolloid-Like MetalloproteinasesADAMTSBiologyBone morphogenetic protein 1Cell Line03 medical and health sciencesDisintegrinHumansHUMAN TISSUE INHIBITORMatrix MetalloproteinaseMolecular BiologyGlycoproteins030304 developmental biologyThrombospondinScience & TechnologyHeparinADAMCell Biology06 Biological SciencesMATRIX-METALLOPROTEINASESProtein Structure TertiaryADAM ProteinsProcollagen peptidaseSULFATED GLYCOSAMINOGLYCANSEnzymologybiology.proteinJournal of Biological Chemistry
researchProduct

Influence of the Urban Exposome on Birth Weight

2019

Background: The exposome is defined as the totality of environmental exposures from conception onwards. It calls for providing a holistic view of environmental exposures and their effects on human health by evaluating multiple environmental exposures simultaneously during critical periods of life. Objective: We evaluated the association of the urban exposome with birth weight. Methods: We estimated exposure to the urban exposome, including the built environment, air pollution, road traffic noise, meteorology, natural space, and road traffic (corresponding to 24 environmental indicators and 60 exposures) for nearly 32,000 pregnant women from six European birth cohorts. To evaluate associatio…

Health Toxicology and Mutagenesis05 Environmental Sciences010501 environmental sciencesToxicology01 natural sciencesCohort Studies0302 clinical medicineUSE REGRESSION-MODELSPregnancy11. SustainabilitySANTEWIDE ASSOCIATIONBirth WeightResearch article030212 general & internal medicinereproductive and urinary physiology11 Medical and Health Sciencesmedia_commonPeer reviewEuropeGeographyFemaleHEALTHmedicine.symptomCohort studyPollutionExposomePRETERM BIRTHBirth weightmedia_common.quotation_subject03 medical and health sciencesPOLLUTIONEnvironmental healthmedicineHumansRESIDENTIAL GREENNESSCities0105 earth and related environmental sciencesLand useLAND-USEResearchEXPOSOMEPublic Health Environmental and Occupational HealthInfant NewbornEnvironmental ExposureAMBIENT AIR-POLLUTIONCHILD COHORT13. Climate action[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieCOHORT PROFILE[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieVEGETATIONVegetation (pathology)
researchProduct

Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990-2019: a systema…

2020

Publisher's version (útgefin grein)

Index (economics)Servicios de SaludSUSTAINABLE DEVELOPMENT GOALS030204 cardiovascular system & hematologyuniversal health coverage; sustaibale develpment goal; global burden of disease; performance;universal health coveragesystematic analysisGlobal Burden of Disease0302 clinical medicineUniversal Health InsuranceRA042111. SustainabilityPer capitaMedical economicsDisease030212 general & internal medicine10. No inequality11 Medical and Health Scienceseffective coverage of health servicesGBD 2019 Universal Health Coverage Collaboratorseducation.field_of_studyPublic healthMedical careSjúkdómar4. Education1. No povertyHealth coveragePublic Health Global Health Social Medicine and EpidemiologyGeneral MedicineHälsovetenskaper3142 Public health care science environmental and occupational healthHealth services3. Good healthGlobal burden of diseaseGlobal Burden of Disease; Health Expenditures; Humans; Universal Health Insurance; World Health OrganizationPurchasing power parityScale (social sciences)/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingLýðheilsauniversal health coveragCANCER SURVIVALACCESSperformanceHumanHeilsuhagfræðimedicine.medical_specialtyHealth coverage GBDGBDUniversal healthGBD 2019Population2019Health expenditures3122 CancersPopulation healthWorld Health Organization03 medical and health sciencesHealth systemsHeilbrigðisvísindiSDG 3 - Good Health and Well-beingGeneral & Internal MedicineDevelopment economicsHealth SciencesmedicineHeilbrigðisstefnasustaibale develpment goalAlþjóðaheilbrigðisstofnuninHumansQUALITYGlobal Burden of Disease StudyeducationPROGRESSDisease burdenPublic healthHealth services accessibilityCAREHeilbrigðisþjónusta//purl.org/pe-repo/ocde/ford#3.02.00 [https]Health ExpenditureFolkhälsovetenskap global hälsa socialmedicin och epidemiologi3121 General medicine internal medicine and other clinical medicineMorbilityAdministración de los Servicios de SaludMedical policyBusinessHealth ExpendituresHeilbrigðiskerfi
researchProduct

Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.

2017

BACKGROUND Degludec is an ultralong-Acting, once-daily basal insulin that is approved for use in adults, adolescents, and children with diabetes. Previous open-label studies have shown lower day-To-day variability in the glucose-lowering effect and lower rates of hypoglycemia among patients who received degludec than among those who received basal insulin glargine. However, data are lacking on the cardiovascular safety of degludec. METHODS We randomly assigned 7637 patients with type 2 diabetes to receive either insulin degludec (3818 patients) or insulin glargine U100 (3819 patients) once daily between dinner and bedtime in a double-blind, treat-To-Target, event-driven cardiovascular outco…

Insulin degludecBlood GlucoseMalemedicine.medical_treatmentDEVOTE Study GroupInsulin GlargineType 2 diabetesKaplan-Meier Estimate030204 cardiovascular system & hematologylaw.inventiondiabetes ; insulin0302 clinical medicineRandomized controlled triallawCardiovascular DiseaseGLUCOSE CONTROL11 Medical and Health SciencesRISKCOMPLICATIONSOUTCOMESIncidenceGeneral MedicineMiddle AgedInsulin Long-ActingVARIABILITYCardiovascular Diseasesdiabetes mellitusFemaleLife Sciences & BiomedicineHumanmedicine.drugmedicine.medical_specialty030209 endocrinology & metabolismAged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus Type 2; Double-Blind Method; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Insulin Glargine; Insulin Long-Acting; Kaplan-Meier Estimate; Male; Middle Aged; Medicine (all)HypoglycemiaBedtimeArticleEVENTS03 medical and health sciencesHYPOGLYCEMIAMedicine General & InternalDouble-Blind MethodInternal medicineDiabetes mellitusGeneral & Internal MedicinemedicineHumansHypoglycemic AgentsIntensive care medicineMETAANALYSISAgedScience & TechnologyHypoglycemic AgentInsulin glarginebusiness.industryInsulinmedicine.diseaseDiabetes Mellitus Type 2businessBASAL INSULIN
researchProduct

Mapping geographical inequalities in childhood diarrhoeal morbidity and mortality in low-income and middle-income countries, 2000-17: analysis for th…

2020

Background: Across low-income and middle-income countries (LMICs), one in ten deaths in children younger than 5 years is attributable to diarrhoea. The substantial between-country variation in both diarrhoea incidence and mortality is attributable to interventions that protect children, prevent infection, and treat disease. Identifying subnational regions with the highest burden and mapping associated risk factors can aid in reducing preventable childhood diarrhoea. Methods: We used Bayesian model-based geostatistics and a geolocated dataset comprising 15 072 746 children younger than 5 years from 466 surveys in 94 LMICs, in combination with findings of the Global Burden of Diseases, Injuri…

Low income countriesmedicine.medical_treatment030204 cardiovascular system & hematologyGlobal HealthTHERAPYGlobal Burden of Disease0302 clinical medicinePrevalenceGlobal healthMedicineWATER030212 general & internal medicineChildren11 Medical and Health SciencesIncidenceMortality rateIncidence (epidemiology)1. No povertyGeneral Medicine3142 Public health care science environmental and occupational healthDiarrhoea3. Good healthChild PreschoolMiddle income countriesA990 Medicine and Dentistry not elsewhere classifiedTERRITORIESLife Sciences & BiomedicineInfantsDiarrheaAFRICAmedicine.medical_specialtyChildhood deathsRJsanitationDeveloping countryChildhood diarrhoeal morbidityITC-HYBRID03 medical and health sciencesMedicine General & InternalGeneral & Internal MedicineEnvironmental healthSYSTEMATIC ANALYSISLife ScienceHumansHealthcare DisparitiesOral rehydration therapyRisk factorhand washingDeveloping CountriesDisease burdenGlobal NutritionWereldvoedingScience & TechnologySEX-SPECIFIC MORTALITYbusiness.industryCHOLERAPublic healthBayes Theoremdiarrheal diseaseLocal Burden of Disease Diarrhoea CollaboratorsITC-ISI-JOURNAL-ARTICLENAHuman medicineDiarreabusiness
researchProduct

Mapping risk factors for depression across the lifespan: An umbrella review of evidence from meta-analyses and Mendelian randomization studies

2018

The development of depression may involve a complex interplay of environmental and genetic risk factors. PubMed and PsycInfo databases were searched from inception through August 3, 2017, to identify meta-analyses and Mendelian randomization (MR) studies of environmental risk factors associated with depression. For each eligible meta-analysis, we estimated the summary effect size and its 95% confidence interval (CI) by random-effects modeling, the 95% prediction interval, heterogeneity with I 2 , and evidence of small-study effects and excess significance bias. Seventy meta-analytic reviews met the eligibility criteria and provided 134 meta-analyses for associations from 1283 primary studie…

MOOD DISORDERSPUBLISHED LITERATURELongevityPsycINFORisk Assessment17 Psychology And Cognitive Sciences03 medical and health sciencesUmbrella review0302 clinical medicineMendelian randomizationIMPAIRED GLUCOSE-METABOLISMmedicineHumansOLDER-ADULTSBiological PsychiatryDepression (differential diagnoses)PsychiatryScience & Technologybusiness.industryDepressionPreventiongenetic risk factorPrediction intervalMAJOR DEPRESSION11 Medical And Health SciencesMendelian Randomization Analysismedicine.diseaseADEQUATE PARENTAL CAREMental healthConfidence intervalADULT DEPRESSION030227 psychiatryDepression; Meta-analyses; Prevention; Psychiatry; Risk factors; Umbrella reviewSYSTEMATIC REVIEWSPsychiatry and Mental healthSystematic reviewMood disordersRisk factorsMeta-analysesINDIVIDUAL PARTICIPANT DATAbusinessLife Sciences & BiomedicineMENTAL-HEALTH030217 neurology & neurosurgeryDemography
researchProduct

Mapping age- and sex-specific HIV prevalence in adults in sub-Saharan Africa, 2000–2018

2022

Abstract Background Human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS) is still among the leading causes of disease burden and mortality in sub-Saharan Africa (SSA), and the world is not on track to meet targets set for ending the epidemic by the Joint United Nations Programme on HIV/AIDS (UNAIDS) and the United Nations Sustainable Development Goals (SDGs). Precise HIV burden information is critical for effective geographic and epidemiological targeting of prevention and treatment interventions. Age- and sex-specific HIV prevalence estimates are widely available at the national level, and region-wide local estimates were recently published for adults overall. We…

MaleAdultSettore MED/17 - Malattie InfettiveAdolescentSettore MED/42 - Igiene Generale e ApplicataHIV InfectionsSettore MED/01 - Statistica MedicaYoung AdultHIV Infections/prevention & controlPregnancySeroepidemiologic StudiesGeneral & Internal MedicinePrevalenceHumansGeostatisticsAfrica; Demographics; Geostatistics; HIV; HIV prevalence; Mapping; Spatial statistics11 Medical and Health SciencesAfrica South of the SaharaAcquired Immunodeficiency SyndromeSpatial statisticsAcquired Immunodeficiency Syndrome/epidemiologyHIVGeneral MedicineMiddle AgedSettore SECS-S/04 - DemografiaAfrica South of the Sahara/epidemiology3142 Public health care science environmental and occupational healthHIV prevalenceMapping3121 General medicine internal medicine and other clinical medicineAfricaDemographicsFemaleBMC Medicine
researchProduct

Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for …

2015

Background Up-to-date evidence on levels and trends for age-sex-specific all-cause and cause-specific mortality is essential for the formation of global, regional, and national health policies. In the Global Burden of Disease Study 2013 (GBD 2013) we estimated yearly deaths for 188 countries between 1990, and 2013. We used the results to assess whether there is epidemiological convergence across countries. Methods We estimated age-sex-specific all-cause mortality using the GBD 2010 methods with some refinements to improve accuracy applied to an updated database of vital registration, survey, and census data. We generally estimated cause of death as in the GBD 2010. Key improvements included…

MaleAgingPediatricsNutrition and DiseaseDatabases FactualDisease030204 cardiovascular system & hematologyGlobal HealthMedical and Health SciencesDOUBLE-BLIND0302 clinical medicineAdolescent; Adult; Aged; Aged 80 and over; Cause of Death; Child; Child Mortality; Child Preschool; Databases Factual; Female; Global Health; Humans; Infant; Infant Newborn; Life Expectancy; Life Tables; Male; Middle Aged; Models Statistical; Mortality; Sex Distribution; Young AdultModelsVoeding en ZiekteCause of DeathEpidemiologyGlobal health80 and over2.2 Factors relating to the physical environmentLife Tables030212 general & internal medicineAetiologyChildINFLUENZAE TYPE-B11 Medical and Health SciencesCause of deathPediatricAged 80 and overPLACEBO-CONTROLLED-TRIALLife TableMortality rateMedicine (all)1. No povertyGeneral MedicineCHILDHOOD PNEUMONIAMiddle AgedStatistical3. Good healthInfectious DiseasesChild PreschoolPNEUMOCOCCAL CONJUGATE VACCINEChild MortalityFemaleInfectionLife Sciences & BiomedicineHumanAdultmedicine.medical_specialtyAdolescentINTEGRATED APPROACHCHILDREN YOUNGER187 COUNTRIESDatabase03 medical and health sciencesDatabasesYoung AdultMedicine General & InternalLife ExpectancyGeneral & Internal MedicinemedicineLife ScienceHumansMortalitySex DistributionPreschoolFactualVLAGAgedScience & TechnologyModels Statisticalbusiness.industryPreventionPOPULATION HEALTHInfant NewbornENTERIC MULTICENTERInfantGBD 2013 Mortality and Causes of Death CollaboratorsNewbornVerbal autopsyChild mortalityGood Health and Well BeingLife expectancyRISK-FACTORSbusiness2.4 Surveillance and distributionDemographyModel
researchProduct

Liraglutide and cardiovascular outcomes in type 2 diabetes

2016

The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. METHODS In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo. The primary composite outcome in the time-to-event analysis was the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The primary hypothesis was that liraglutide would be noninferior to placebo with regard to the primary outcome, with a margin of 1.30 for the upper boundary of the 95% confidence interval of the hazard ratio. No adjus…

MaleGastrointestinal DiseasesTreatment outcomeClinical BiochemistryMyocardial InfarctionType 2 diabetes030204 cardiovascular system & hematologylaw.inventionMedicine; Endocrinology0302 clinical medicineRandomized controlled trialAged; Cardiovascular Diseases; Diabetes Mellitus Type 2; Double-Blind Method; Female; Gastrointestinal Diseases; Humans; Hypoglycemic Agents; Liraglutide; Male; Middle Aged; Myocardial Infarction; Stroke; Treatment Outcome; Medicine (all)lawCardiovascular DiseaseClinical-trial; Pancreatitis; Therapies; Cancer; Drugs11 Medical and Health SciencesResearch Support Non-U.S. Gov'tMedicine (all)PANCREATITISHazard ratioLEADER Steering CommitteeFollow up studiesGeneral MedicineMiddle AgedAlbiglutideMulticenter StudyStrokeTRIALSTreatment OutcomeCardiovascular DiseasesRandomized Controlled TrialFemaleLife Sciences & BiomedicineCardiovascular outcomesmedicine.drugHumanmedicine.medical_specialtyGastrointestinal DiseaseMEDLINE030209 endocrinology & metabolismLEADER Trial InvestigatorsPlaceboFollow-Up Studie03 medical and health sciencesMedicine General & InternalResearch Support N.I.H. ExtramuralDouble-Blind MethodGeneral & Internal MedicineDiabetes mellitusInternal medicinemedicineJournal ArticleHumansHypoglycemic AgentsAgedGlycemic efficacyScience & TechnologyHypoglycemic AgentLiraglutidebusiness.industrySemaglutideLiraglutidemedicine.diseaseSurgeryDiabetes Mellitus Type 2businessFollow-Up Studies
researchProduct